SALMONELLA

Volver

Resultados 58 resultados LastUpdate Última actualización 13/11/2018 [16:34:00] pdf PDF




Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days



Página1 de 3 nextPage   Mostrar por página


SALMONELLA AND IMMUNOGENIC COMPOSITION CONTAINING THE SAME AS WELL AS ITS USE

NºPublicación: WO2018197621A1 01/11/2018

Solicitante:
HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH [DE]

Resumen de: WO2018197621A1

In a first aspect, the present invention relates to a mutated Salmonella strain comprising mutations in flagellin II genes, like the fliF gene, in particular, in addition the aroA gene, the IpxR gene, the pagP gene, the pagL gene, the ydiV gene and optionally the eptA gene and further optionally, the arnT gene. In a further aspect, immunogenic compositions comprising said Salmonella strain are provided optionally together with a pharmaceutically accepted carrier, diluent or effluent. Moreover, a method for producing outer membrane vesicles of Salmonella is provided, said method comprises the steps of cultivating the Salmonella strain according to the present invention and isolating the outer membrane vesicles accordingly. The present invention provides the bacteria or the outer membrane vesicles (OMVs) obtainable by the methods according to the present invention and its use as a transport moiety or as an immunogenic composition, like a vaccine or immunotherapy platform espedaily for therapeutic treatment of cancer of tissue or blood.



traducir


 

ANTIBODIES TARGETING A MANNAN-BASED O-ANTIGEN OF K. PNEUMONIAE

NºPublicación: US2018312576A1 01/11/2018

Solicitante:
ARSANIS BIOSCIENCES GMBH [AT]

Resumen de: US2018312576A1

The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.



traducir


 

METHOD TO ENHANCE IMMUNOGENICITY OF LIVE TYPHOID VACCINES AND CARRIERS

NºPublicación: US2018312550A1 01/11/2018

Solicitante:
UNIV ARIZONA STATE [US]

Resumen de: US2018312550A1

In certain embodiments, the present invention provides a recombinant Salmonella enterica serovar Typhi cell, vaccines and compositions, and methods of use thereof.



traducir


 

NOVEL MUCOSAL ADJUVANTS AND DELIVERY SYSTEMS

NºPublicación: EA201891124A2 31/10/2018

Solicitante:
\u0414\u0417\u0415 \u0411\u041E\u0420\u0414 \u041E\u0424 \u0422\u0420\u0410\u0421\u0422\u0418\u0417 \u041E\u0424 \u0414\u0417\u0415 \u042E\u041D\u0418\u0412\u0415\u0420\u0421\u0418\u0422\u0418 \u041E\u0424 \u0410\u0420\u041A\u0410\u041D\u0417\u0410\u0421

Resumen de: WO2014070709A1

Adjuvants comprising chitosan cross-linked with, an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used, in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.



traducir


 

ANTIBODIES TARGETING A MANNAN-BASED O-ANTIGEN OF K. PNEUMONIAE

NºPublicación: CN108699137A 23/10/2018

Solicitante:
\u963F\u5C14\u8428\u5C3C\u65AF\u751F\u7269\u79D1\u5B66\u6709\u9650\u8D23\u4EFB\u516C\u53F8

Resumen de: WO2017071835A1

The invention provides for an isolated antibody that specifically recognizes an epitope of the lipopolysaccharide (LPS) O3b-antigen structure of Klebsiella pneumoniae, which is a O3b-epitope incorporated in O3b-antigen comprising the structure of Formula (I), including one or more O3b-antigen mannose homopolymer repeating units, wherein MeP is methyl phosphate; and n is 0-50. The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.



traducir


 

Immune modulator for the control of hypersensitivity due to house dust mite-derived allergens

NºPublicación: CN108697784A 23/10/2018

Solicitante:
MD\u4FDD\u5065\u682A\u5F0F\u4F1A\u793E

Resumen de: CN108697784A

本发明涉及种用于预防或治疗由屋尘螨来源的过敏原引起的过敏性疾病的免疫调节剂。具体地而言,本发明提供种免疫调节药物组合物及其制备方法,所述免疫调节组合物包含含有北美屋尘螨或欧洲屋尘螨来源的过敏原的细菌的细胞外囊泡作为有效成分。



traducir


 

yfeC/D基因敲除重组志贺氏菌的制备及应用

NºPublicación: CN108690824A 23/10/2018

Solicitante:
\u4E2D\u56FD\u4EBA\u6C11\u89E3\u653E\u519B\u519B\u4E8B\u79D1\u5B66\u9662\u519B\u4E8B\u533B\u5B66\u7814\u7A76\u9662

Resumen de: CN108690824A

本发明公开了yfeCD基因敲除重组志贺氏菌的制备及应用。本发明提供了种构建重组菌的方法,为抑制或沉默福氏志贺氏菌基因组上的yfeCD基因表达,得到重组菌。本发明利用λRED同源重组的方法成功敲除了301中的yfeC/D基因,得到yfeC/D基因缺失株,并利用豚鼠角膜实验、III型分泌系统诱导分泌及小鼠肺竞争性侵袭三个毒力评价模型,初步断定其中yfeC/D基因缺失株的毒力有明显减弱,表明yfeC/D基因在志贺氏菌致病过程中有可能起到重要作用,得到的yfeC/D基因缺失株可以用作减毒疫苗的制备。



traducir


 

Protein Particles Comprising Disulfide Crosslinkers and Uses Related Thereto

NºPublicación: US2018296635A1 18/10/2018

Solicitante:
UNIV EMORY [US]
GEORGIA TECH RES INST [US]

Resumen de: US2018296635A1

This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds. Typically the recombinant protein has a polypeptide of viral, fungal, or bacterial origin such as secreted effector proteins AvrA and YopJ. In certain embodiments, the disclosure relates to treating or preventing autoimmune diseases, cancer, or inflammatory diseases, or conditions such as inflammatory bowel disease (IBD).



traducir


 

DEVICES, SYSTEMS, AND METHODS FOR THE DETECTION OF ANALYTES

NºPublicación: US2018299403A1 18/10/2018

Solicitante:
PROTEOSENSE [US]

Resumen de: US2018299403A1

Disclosed are devices, systems, and methods for the rapid and accurate detection of analytes, including Salmonella.



traducir


 

BACTERICIDAL MONOCLONAL ANTIBODY TARGETING KLEBSIELLA PNEUMONIAE

NºPublicación: US2018298084A1 18/10/2018

Solicitante:
ARSANIS BIOSCIENCES GMBH [AT]

Resumen de: US2018298084A1

A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-II antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.



traducir


 

Compositions and methods for detecting gastrointestinal pathogen nucleic acid

NºPublicación: AU2018236835A1 18/10/2018

Solicitante:
GEN PROBE INCORPORATED

Resumen de: AU2018236835A1

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGEN NUCLEIC ACID Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacterjejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.



traducir


 

Compositions and methods for detecting gastrointestinal pathogen nucleic acid

NºPublicación: AU2018236857A1 18/10/2018

Solicitante:
GEN PROBE INCORPORATED

Resumen de: AU2018236857A1

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGEN NUCLEIC ACID Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacterjejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.



traducir


 

Compositions and methods for detecting gastrointestinal pathogen nucleic acid

NºPublicación: AU2018236838A1 18/10/2018

Solicitante:
GEN PROBE INCORPORATED

Resumen de: AU2018236838A1

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGEN NUCLEIC ACID Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacterjejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.



traducir


 

Compositions and methods for detecting gastrointestinal pathogen nucleic acid

NºPublicación: AU2018236842A1 18/10/2018

Solicitante:
GEN PROBE INCORPORATED

Resumen de: AU2018236842A1

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGEN NUCLEIC ACID Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacterjejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.



traducir


 

BIRD FEED AND IN PARTICULAR POULTRY FEED, COMPRISING SYNTHETIC CAPSAICINOID DERIVATIVES AND SUCH FEED FOR PROHYLACTIC USE OR TREATMENT OF SALMONELLA INFECTION

NºPublicación: PH12018500772A1 15/10/2018

Solicitante:
AXICHEM AB [NO]

Resumen de: PH12018500772A1

The invention relates to bird feed comprising synthetic capsaicinoids for prohylactic use or treatment of salmonella infection.



traducir


 

NOVEL MUCOSAL ADJUVANTS AND DELIVERY SYSTEMS

NºPublicación: AU2018232919A1 04/10/2018

Solicitante:
UNIV ARKANSAS

Resumen de: AU2018232919A1

Abstract Adjuvants comprising chitosan cross-linked with, an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used, in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject. c EE " *> * sO 0M V> + c QD~~ pl 1 P110OLUPS 1 A-8A03H WOJ4



traducir


 

A BIVALENT OUTER MEMBRANE VESICLES (BOMVS) BASED VACCINE AGAINST TYPHOIDAL SALMONELLAE

NºPublicación: WO2018179003A2 04/10/2018

Solicitante:
INDIAN COUNCIL MEDICAL RES [IN]

Resumen de: WO2018179003A2

A novel consortium used as potent vaccine for treating of enteric fever, comprised of isolated Outer Membrane Vesicles (OMVs) taken from two different strains of typhoidal Salmonella species.



traducir


 

VACCINE FOR LIVESTOCK PRODUCTION SYSTEMS

NºPublicación: RU2017110230A 01/10/2018

Solicitante:
\u0414\u0417\u0415 \u0420\u0418\u0414\u0416\u0415\u041D\u0422\u0421 \u041E\u0424 \u0414\u0417\u0415 \u042E\u041D\u0418\u0412\u0415\u0420\u0421\u0418\u0422\u0418 \u041E\u0424 \u041A\u0410\u041B\u0418\u0424\u041E\u0420\u041D\u0418\u0410

Resumen de: WO2016033532A1

The invention relates to a live vaccine for protection against enteric bacterial infection.



traducir


 

Novel Salmonella Typhimurium strain and vaccine composition comprising the same

NºPublicación: KR20180105945A 01/10/2018

Solicitante:
REPUBLIC OF KOREA ANIMAL AND PLANT QUARANTINE AGENCY [KR]

Resumen de: KR20180105945A

본 발명은 신규한 살모넬라 타이피뮤리움 균주 및 이를 포함하는 살모넬라 타이피뮤리움 감염증의 예방용 백신 조성물에 관한 것으로, 보다 구체적으로는 수탁번호 KCTC13198BP로 수탁된 살모넬라 타이피뮤리움 균주 ST26, 이를 포함하는 살모넬라 타이피뮤리움 감염증의 예방용 백신 조성물, 백신 조성물의 제조방법 및 상기 백신 조성물을 개체에 투여하여 살모넬라 타이피뮤리움 감염증을 예방하는 방법에 관한 것이다. 가금류로부터 분리된 본 발명의 신규한 살모넬라 타이피뮤리움 균주는 병원성이 높은 균주로서, 높은 안전성, 면역원성 및 방어능을 가지고 있는 바, 본 발명의 신규한 살모넬라 타이피뮤리움 균주를 포함하는 백신 조성물은 가금류 농가의 생산 안정성뿐만 아니라 인간에서의 살모넬라 타이피뮤리움 감염증 발생을 예방하는 데 유용하게 이용될 수 있다.



traducir


 

BACTERICIDAL MONOCLONAL ANTIBODY TARGETING KLEBSIELLA PNEUMONIAE

NºPublicación: CN108602880A 28/09/2018

Solicitante:
\u963F\u5C14\u8428\u5C3C\u65AF\u751F\u7269\u79D1\u5B66\u6709\u9650\u8D23\u4EFB\u516C\u53F8

Resumen de: WO2017064258A1

A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-ll antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.



traducir


 

Production and application of protozoa cultures of Histomonas meleagridis (H. meleagridis)

NºPublicación: JP2018148893A 27/09/2018

Solicitante:
\u30D5\u30A7\u30C6\u30EA\u30CD\u30FC\u30EB\u30E1\u30C7\u30A3\u30C4\u30A3\u30CB\u30B7\u30E5 \u30A6\u30CB\u30D9\u30EB\u30B8\u30C6\u30FC\u30C8 \u30A6\u30A3\u30FC\u30F3

Resumen de: EP2682457A1

The invention discloses a method for producing a single bacterial strain culture of Histomonas meleagridis (H. meleagridis), the method being characterised by the following steps: (a) providing a xenic culture of H. meleagridis comprising H. meleagridis cells with a wild type bacterial flora, (b) treating the xenic culture with a mixture of antibiotics thereby killing the wild type bacterial flora, (c) centrifuging and washing the H. meleagridis cells, (d) controlling effectiveness of step (b), (e) resuspending the washed H. meleagridis cells, (f) adding one or more single bacterial strain(s) to the resuspended H. meleagridis cells, and (g) culturing the one or more single bacterial strain(s) with the resuspended H. meleagridis cells so as to obtain a single bacterial strain culture of H. meleagridis. The invention further discloses a vaccine formulation consisting of a Histomonas component consisting of an attenuated culture of Histomonas meleagridis, a bacterial component consisting of one or more cultures of a single bacterial strain, and pharmaceutically acceptable non-biological formulation compounds.



traducir


 

DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME

NºPublicación: JP2018527882A 27/09/2018

Solicitante:
\u30E2\u30EC\u30AD\u30E5\u30E9\u30FC \u30C6\u30F3\u30D7\u30EC\u30FC\u30C4\uFF0C\u30A4\u30F3\u30AF\uFF0E\uFF2D\uFF2F\uFF2C\uFF25\uFF23\uFF35\uFF2C\uFF21\uFF32 \uFF34\uFF25\uFF2D\uFF30\uFF2C\uFF21\uFF34\uFF25\uFF33\uFF0C \uFF29\uFF2E\uFF23\uFF0E

Resumen de: WO2016196344A1

The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.



traducir


 

BACTERIOCINS FOR CONTROL OF SALMONELLA ENTERICA

NºPublicación: WO2018172065A1 27/09/2018

Solicitante:
NOMAD BIOSCIENCE GMBH [DE]

Resumen de: WO2018172065A1

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.



traducir


 

BACTERIOCINS FOR CONTROL OF SALMONELLA ENTERICA

NºPublicación: EP3378485A1 26/09/2018

Solicitante:
NOMAD BIOSCIENCE GMBH [DE]

Resumen de: EP3378485A1

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.



traducir


 

NOVEL PD-L1 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY

Nº publicación: WO2018167290A1 20/09/2018

Solicitante:
VAXIMM AG [CH]

Resumen de: WO2018167290A1

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain of Salmonella for use in the treatment of cancer.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver